Short summary: A large real-world study presented at ENDO 2026 found that adults with type 2 diabetes who were prescribed semaglutide had fewer recorded bone fractures than adults prescribed several other weight-loss medicines. The result is encouraging, but it is not proof that semaglutide prevents fractures.
What happened?
Researchers reviewed electronic health record data from more than 59,000 adults with type 2 diabetes. They compared people who received semaglutide with people who received dulaglutide, phentermine/topiramate, or bupropion/naltrexone.
The analysis included adults with type 2 diabetes who had no previous fracture history and had not used osteoporosis medicines. In the unmatched study population, 26,324 people were in the semaglutide group and 33,555 people were in the comparison group.
What did the ENDO 2026 study find?
After an average follow-up of about 1,327 days, researchers recorded 794 fracture events in the semaglutide group and 1,045 fracture events in the comparison group. After matching and adjustment, semaglutide use was associated with about a 15% lower fracture risk.
The semaglutide group also had greater average body mass index reduction among people with available BMI data. That makes the finding notable, because weight loss can sometimes raise concern about bone loss or fracture risk.
Why this matters
Fractures can be painful, costly, and harder to recover from with age. Because GLP-1 medicines such as semaglutide are now widely used for diabetes and weight management, patients and clinicians need better evidence about longer-term effects beyond blood glucose and weight.
This study is useful because it asks a practical question: when people with type 2 diabetes use semaglutide for metabolic treatment, what happens to fracture risk compared with other weight-loss medicines?
What other evidence says
A PubMed-indexed target trial emulation also reported that, among people with obesity and type 2 diabetes, semaglutide initiation was associated with lower major osteoporotic fracture risk compared with empagliflozin, glipizide, and usual care. The same paper reported no significant major osteoporotic fracture association in people with obesity who did not have type 2 diabetes.
Another PubMed-indexed retrospective study found that bone effects with semaglutide or tirzepatide may differ by diabetes status, and that weight loss was linked with bone loss in some groups. Taken together, these studies support more research rather than a simple claim that semaglutide protects bones.
The important caveat
This was a retrospective observational study, not a randomized trial. That means it can show an association, but it cannot prove that semaglutide itself caused fewer fractures.
Even with matching methods, people prescribed semaglutide may differ from people prescribed other medicines in ways that are not fully captured in health records. The ENDO 2026 summary notes that prospective studies are needed before this finding should be treated as proof of a bone-protective effect.
Practical takeaway
If you take semaglutide, this study is reassuring but not a reason to start, stop, or change treatment on your own. It is also not a reason to use semaglutide mainly for bone protection.
If you have type 2 diabetes and are using weight-loss treatment, it is reasonable to ask your clinician whether bone health, fracture history, falls risk, or bone-health monitoring should be part of your broader care plan. This is especially relevant if you are older, have had a previous fracture, or already have concerns about bone strength.
Evidence and source summary
- Study type: Retrospective cohort study using electronic health record data.
- Population: Adults with type 2 diabetes, no previous fracture history, and no osteoporosis medication use.
- Semaglutide group: 26,324 people, with 794 fracture events reported.
- Comparison group: 33,555 people using dulaglutide, phentermine/topiramate, or bupropion/naltrexone, with 1,045 fracture events reported.
- Main ENDO 2026 finding: Semaglutide use was associated with about 15% lower fracture risk after matching and analysis.
- Limit: Observational findings cannot prove cause and effect.
Sources
- MedCentral: The Endocrine Society 2026 Research Roundup
- PubMed: Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes
- PubMed: Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures
How we checked this article
OpenAI medical accuracy review: The draft was checked for patient-safety framing, unsupported claims, drug names, study design, statistics, and exaggeration. The wording was kept cautious because the evidence is observational.
OpenRouter/Perplexity verification: The main claims and numbers were checked against cited ENDO 2026 and PubMed source material. Verification supported publication with clear caveats that the finding is an association and needs prospective confirmation.
This article is for general education only and does not replace care from your own clinician.